-
A Phase 1b/2 Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer.
You can participate in this study if you are diagnosed with histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of the colon or rectum. The ... -
A Phase 1/2 Open-label Study to Investigate the Safety Efficacy and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults with Relapsed or Refractory B cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)
This study is designed for patients diagnosed with relapsed or refractory B cell precursor acute lymphoblastic leukemia (R/R B-ALL).
This study is a 2-part ...
-
A PHASE 1/2 DOSE ESCALATION STUDY OF THE BCL-2 INHIBITOR ZN-d5 AND THE WEE1 INHIBITOR ZN-c3 IN SUBJECTS WITH ACUTE MYELOID LEUKEMIA ZN-d5-004C
This study is designed for patients with acute myeloid leukemia.
The study is a phase 1/2 dose escalation study of the BCL-2 Inhibitor ZN-d5 ...
-
A Phase 1/2 First-in-Human Study of DCC-3116 as Monotherapy and in Combination with RAS/MAPK Pathway Inhibitors in Patients with Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway Mutations
This study is designed for patients who have Advanced or Metastatic Solid Tumors with RAS/MAPK Pathway MutationsThe objective of the study is to ...
-
Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
This study is designed for patients diagnosed with advanced solid tumors and is testing a novel epigenetic modifying strategy to restore tumor cell differentiation.
The ...
-
EVEREST-1: A Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B530 an Autologous Logic-gated Tmod Chimeric Antigen Receptor T Cell (CAR T) in Heterozygous HLA-A*02 Adult Subjects with Recurrent Unresectable Locally Advanced or Metastatic Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
This is a study to see if a new treatment called A2B530 is safe and effective for people with certain types of cancer that have ...
-
A Phase 1/2 Open-Label Study to Evaluate the Safety Tolerability Pharmacokinetics and Efficacy of TNG260 as Single Agent and in Combination with an anti-PD-1 Antibody in Patients with STK11-Mutated Advanced Solid Tumors
This study is testing a new drug called TNG260 (a specific medicine referred to as a CoreDAC inhibitor that can undo the way the immune ...
-
Phase 1b/2a Study of Gemcitabine and Nab-paclitaxel in Combination with VS-6766 and Defactinib in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas
This study is about testing a combination of drugs (gemcitabine, nab-paclitaxel, VS-6766, and defactinib) to treat a type of cancer called pancreatic ductal adenocarcinoma (PDAC ...
-
A dose escalation and expansion study of sonodynamic therapy with SONALA-001 in combination with Exablate 4000 Type-2 MR-guided focused ultrasound in patients with recurrent or progressive glioblastoma multiforme
This is a study testing a new non-invasive treatment called sonodynamic therapy (SDT) for recurrent or progressive glioblastoma (GBM). The study team will use intravenous ...
-
A Phase I/II Open-Label Multicenter Study to Assess the Safety Tolerability Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR or HER2 mutation
A Phase I/II, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Efficacy of DZD9008 in Patients with Advanced Non-Small Cell Lung ...